Cost Analysis: Whole Exome Sequencing vs Other NGS Approaches

With the rapid development of genomics, next-generation sequencing (NGS) technology has become an important tool in biomedical research. Among them, whole exome sequencing (WES) and other NGS methods, such as whole genome sequencing (WGS) and targeted sequencing, each have their unique advantages and applicable scenarios. This article will conduct a cost analysis of whole exome sequencing and other NGS methods from multiple perspectives to help researchers and clinicians make informed choices.

I. Technical Definitions and Core Differences

Whole Exome Sequencing (WES)

• Target Range: Covers approximately 1-2% of the exon regions of the genome (approximately 30 Mb), containing protein-coding regions of approximately 20,000 genes.
• Technical Workflow:
  • Probe Capture: Exon DNA is enriched using biotinylated probes. Probe design needs to be optimized to reduce off-target effects (non-specific capture).
  • Sequencing Depth: An average sequencing depth of 100–200× is typically recommended. At this depth, it can be expected that ≥95% of the target regions achieve a coverage depth of ≥20×, thereby providing a reliable sensitivity foundation for detecting both heterozygous and homozygous SNVs.
• Cost Drivers:
  • Probe Design: Commercial panels (e.g., Agilent SureSelect, IDT xGen) account for 30%-50% of the total sample cost.
  • GC Content Bias: High-GC regions have low capture efficiency, requiring increased sequencing volume to compensate, increasing costs by 10%-20%.

Whole Genome Sequencing (WGS)

• Target Range: Covers all 3 billion bases, including coding regions, introns, regulatory elements, and mitochondrial DNA.
• Technical Challenges:
  • Data Volume: Generates 100-200 GB of raw data per sample, which is approximately 10-20 times larger than typical WES data. This results in proportionally higher long-term data storage costs.
  • Computational Resources: Requires high-performance servers (e.g., GPU acceleration) or cloud-based instances (AWS, Google Cloud, Microsoft Azure) for variant annotation, significantly increasing analysis cost.
• Cost Optimization Strategy: Low-pass sequencing (5–15×) can be employed for specific research purposes, such as genome-wide screening for copy number variations (CNVs) and large-scale structural variations (SVs), significantly reducing costs. However, this depth is not suitable for the detection of somatic single nucleotide variants (SNVs) or small insertions and deletions (Indels) that require high sensitivity.

Targeted Sequencing (Gene Panels)

• Customized Design: Gene combinations are selected based on disease type (e.g., a tumor hotspot gene panel containing 50-500 genes).
• Cost Advantages:
  • Low Data Volume: 1-5 GB/sample, sequencing cost typically $400-2,500, suitable for rapid clinical diagnosis.
  • Flexible Expansion: Genes can be dynamically added or removed to adapt to the needs of new mutation research.
• Limitations:
  • False positive risk: Depends on probe specificity; low-frequency mutations (<5%) are easily masked by background noise and may require orthogonal validation (e.g., ddPCR or Sanger sequencing).

II. Cost Comparison and Key Parameters

Note: Costs are estimates and vary widely based on platform, scale, and whether the test includes clinical interpretation. Research-scale WGS can approach $500/sample on new high-throughput platforms (e.g., Element AVITI), while fully burdened clinical WGS (including analysis, interpretation, and reporting) typically ranges from $2,000 to over $5,000.

Key Cost Difference Analysis

• Sample Preparation: WGS requires higher purity DNA (≥50 ng/μL), with FFPE sample repair costs adding $70-300; WES has lower DNA quality requirements (≥20 ng/μL).
• Sequencing Platform:
  • Illumina NovaSeq 6000/X: A single WGS run can process 12-24 samples, reducing per-sample cost by ~15%; WES costs are more variable due to lower throughput demands.
  • Element AVITI or Ultima Genomics platforms: Emerging platforms are further reducing WGS and WES costs, with Ultima claiming $100 WGS at scale.
• Data Analysis & Storage:
  • WGS: Due to the vast amount of raw data (approximately 30 times larger than WES), computational time, storage overhead, and cloud service costs (AWS S3, Google Cloud Storage, Azure Blob) increase significantly.
  • WES: Mature standardized analysis pipelines exist; open-source tools (e.g., GATK, FreeBayes) can reduce software costs.

Tornado diagram of parameters (equipment, staff and consumables) impacting the costs per exam in the reference and alternative scenarios (Neves LM et al., 2024)

III. Application Scenarios and Cost-Effectiveness Optimization Strategies

Research Scenarios

• WGS: Suitable for the discovery of novel pathogenic genes (e.g., rare disease research) and non-coding variants, but requires integration with functional genomics data (increasing cost by 20%-40%).
• WES: The preferred choice for genetic disease cohort studies, covering over 95% of known pathogenic mutations in coding regions, with a cost approximately 1/3-1/5 of WGS.
• Targeted Panel: Screening for cancer driver genes (e.g., EGFR, KRAS, BRAF in lung cancer, colorectal cancer, melanoma), reducing the cost per test.

Clinical Diagnosis

• Pediatric/Genetic Disease Testing: WES is often used as a first- or second-tier test for unexplained developmental delay, congenital anomalies, or suspected genetic disorders. Reimbursement by insurers (e.g., Medicare, Medicaid, private payers like UnitedHealthcare, Anthem) varies but is increasingly common for specific indications.
• Precision Oncology Treatment:
  • Panel Approach: A 500-gene comprehensive genomic profiling panel (e.g., from Foundation Medicine, Tempus, Caris) typically costs $3,000-5,000 and is often covered by Medicare and many private insurers for advanced cancer. These panels identify FDA-approved targeted therapy indications (e.g., osimertinib for EGFR mutations, entrectinib for NTRK fusions).
  • WGS Approach: Whole-genome analysis can identify fusion genes, complex structural variants, and tumor mutational burden (TMB). The reimbursement landscape for WGS in the U.S. is rapidly evolving. While it is not yet the universal first-line standard-of-care in all community settings, its clinical utility is increasingly recognized by payers. Several states, including Mississippi with its 2025 House Bill 973, have introduced or passed legislation mandating Medicaid coverage for rapid WGS in critically ill children who meet specific criteria. This shift is supported by health economic analyses demonstrating the cost-effectiveness of first-line WGS in specific high-acuity pediatric cohorts, suggesting its role in clinical diagnostics will continue to expand.

Special Needs Optimization

• Low-Frequency Mutation Detection:
  • Increased Sequencing Depth: WES is improved from 100× to 300×, nearly doubling the cost, but increasing sensitivity for subclonal mutations.
  • UMI Technology: Utilizes Unique Molecular Identifiers (UMIs) to reduce PCR amplification bias, increasing cost by 30%, but reducing the false positive rate by 50%, critical for liquid biopsy applications.
• Structural Variation Analysis:
  • WGS Advantages: Can detect inversions and large deletions (>50 bp) and balanced rearrangements, but requires long-read sequencing (e.g., PacBio HiFi, Oxford Nanopore) for complex regions, significantly increasing cost.

IV. Market Trends and Cost Reduction Drivers

Technological Advancements

• Increased Sequencing Throughput: NovaSeq X series and new entrants (Element, Ultima) continue to drive costs down. The cost per WGS sample is projected to approach $200-500 at scale within the next few years.
• Platform Competition: Competition among Illumina, Element, PacBio, Oxford Nanopore, and emerging players is accelerating innovation and price reductions.

Cost Control Strategies

• Hybrid Sequencing: WGS initial screening + orthogonal validation reduces overall costs compared to exhaustive Sanger sequencing of many genes.
• Cloud Service Model & Bioinformatics: Utilizing cloud-based analysis pipelines (e.g., DNAnexus, Seven Bridges, Terra.bio) can reduce local computing infrastructure costs. Archive storage (AWS S3 Glacier Deep Archive, Google Cloud Archive) is significantly cheaper than standard storage for long-term data retention.

Policy & Reimbursement Impact

• Medicare Coverage: Medicare Administrative Contractors (MACs) have established Local Coverage Determinations (LCDs) for WES and large panel testing. The reimbursement landscape for WGS is rapidly evolving, with several states, including Mississippi (2025 House Bill 973), introducing legislation to mandate Medicaid coverage for rapid WGS in critically ill children. While not yet the universal standard-of-care in all community settings, its clinical utility and cost-effectiveness in specific high-acuity pediatric cohorts are increasingly recognized by payers, signaling a shift toward broader adoption.
• FDA Oversight: The FDA regulates NGS tests as medical devices. Clearance/approval pathways (De Novo, 510(k), Premarket Approval) influence the cost and timeline for bringing new panels to market. Requirements for analytical and clinical validation add 20%-30% to development costs for manufacturers. Comparative analysis of US (FDA) and international regulatory requirements for diagnostic reagents is ongoing.
• State-Level Initiatives: State legislation, such as Florida's proposed SB 1552 ("Promising Pathways Act") , may impact access to experimental treatments for terminal conditions, potentially including novel NGS-guided therapies.
• Payer Coverage Policies: Private insurers (e.g., Anthem, Aetna, Cigna, UnitedHealthcare) have their own medical policies for genetic testing, which heavily influence clinical adoption. Coverage often requires evidence of clinical utility and impact on patient management.

V. Cost-Effectiveness Analysis Data of Clinical Cases

Case Study 1: Diagnosis of Pediatric Unexplained Developmental Delay (DD)

• Background: A cost-effectiveness comparison of different genetic testing strategies was conducted for patients with unexplained DD/MCA (multiple congenital anomalies).
• Testing Strategies and Costs (Adapted from Australian Study):

Key Conclusions:

• Optimal Strategy: Using WES + CMA as the first-tier test can be cost-effective by increasing diagnostic yield and potentially reducing the need for multiple other tests (Li C et al., 2021). This aligns with U.S. practice where WES is increasingly used early in the diagnostic odyssey.

Case Study 2: Resistance Monitoring in Non-Small Cell Lung Cancer (NSCLC)

• Background: Within the Dutch stage IV NSCLC diagnostic system, a comparison was made between traditional stepwise testing and direct WGS testing at academic hospitals.
• Cost and Findings: The model showed that optimizing the testing pathway and increasing throughput can achieve a more cost-effective solution while shortening diagnostic time. In the U.S., comprehensive genomic profiling panels (large targeted panels) are now the standard of care, and WGS is being explored in research settings for its potential to capture all variant types in a single assay.

Case Study 3: Genetic Diagnosis of Hereditary Kidney Disease (FSGS)

• Background: Whole Exome Sequencing (WES) was performed on FSGS pedigrees to compare the costs with traditional linkage analysis and candidate gene sequencing.
• Testing Costs and Diagnostic Yield :

Key Conclusions:

• Best Cost-Effectiveness: WES costs slightly more than candidate gene sequencing but significantly increases the detection rate, reducing the need for repeated testing and prolonged diagnostic odysseys.

VI. Comprehensive Analysis

Cost Structure Differences

• WES: High fixed costs for probe design (amortized over many samples). Marginal costs decrease significantly with increasing sample volume and batching.
• WGS: Sequencing and library preparation costs are the primary drivers. Data storage (15–25%) and computational analysis (35–50%) are major ongoing expenses. Utilizing commercial cloud analysis platforms or local high-performance computing clusters adds significant cost.

Clinical Decision Threshold

• Genetic Disease Diagnosis: When the pre-test probability is moderate to high, WES cost-effectiveness often surpasses piecemeal single-gene or small panel testing, especially in critically ill infants (NICU/PICU settings). Coverage of over 95% of known pathogenic mutation-associated genes makes it a powerful diagnostic tool.
• Tumor Surveillance: WES may be valuable for comprehensive profiling in research, but large, FDA-authorized targeted panels are the current clinical standard for detecting guideline-recommended biomarkers in the U.S. due to established reimbursement pathways and evidence of clinical utility.

Policy Impact

• Medicare Coverage: Inclusion of WES and large panels in Medicare LCDs has significantly increased clinical adoption rates since 2020. The Consolidated Appropriations Act, 2026, includes provisions affecting drug pricing (PBM reforms) which may indirectly influence the value proposition of comprehensive genomic testing to guide targeted therapy selection.
• FDA & Regulatory Requirements: The FDA requires NGS kits to pass premarket review or meet special controls. This increases development costs but also ensures a certain level of analytical validity, driving standardization and improving confidence in test results.

VII. Summary and Recommendations

Research Scenarios

• Discovery-Focused: WGS is the preferred choice, providing unbiased whole-genome data suitable for discovering novel pathogenic genes, non-coding variants, and structural variants. Requires sufficient budget ($1,200-$3,000+ per sample at scale).
• Budget-Conscious, Coding Region Focus: Prioritize WES ($300-$900 per sample) combined with functional validation experiments for better cost-effectiveness when the focus is on protein-coding regions.

Clinical Application

• Rapid Diagnosis/Targeted Therapy Guidance: Targeted Panels ($70-$400 laboratory cost; higher billed/reimbursed amounts) are suitable for screening known actionable genes (e.g., oncology panels, cardiomyopathy panels). Reimbursement is well-established for many indications. Panels must be regularly updated to incorporate newly discovered biomarkers and therapies.
• Complex/Undiagnosed Cases: For complex cases (e.g., unexplained genetic disorders), whole-genome sequencing (WGS) offers the most comprehensive view of the genome, including coding, non-coding, and regulatory sequences. This enables detection of various variant types such as point mutations, copy number variations (CNVs), and structural variants. Recent meta-analyses indicate that while the overall diagnostic yield of WGS and WES is comparable in unselected cohorts, WGS provides a modest incremental diagnostic benefit in specific high-risk populations, such as undiagnosed rare disease patients (approximately 1.2-fold). This advantage is largely attributed to its ability to detect non-coding variants and structural variants, whose clinical significance, however, requires further research and validation.

Cost-Sensitive Scenarios

• Large Batches of Samples: Using high-throughput core facilities or platforms with economies of scale can significantly reduce per-sample costs.
• Long-term Cohorts: Pre-store DNA samples and sequence in batches. Combine with cloud-based storage and analysis with pay-as-you-go billing (archive storage costs can be reduced significantly using services like AWS S3 Glacier Deep Archive or Google Cloud Archive).

People Also Ask

Is WGS or WES more expensive?

WGS currently costs two to three times as much as WES, but most of the cost of WGS (>90%) is directly related to sequencing whereas WES cost is mainly due to the capture kit.

What is the difference between NGS and whole exome sequencing?

NGS is a broad category of high-throughput DNA sequencing technologies, while WES is a specific application of NGS that targets and sequences only the protein-coding regions (exons) of the genome.

Why is WES better than WGS?

One of the major advantages of WES is that it is a cost-effective way to sequence a large number of samples. Since only the exome is sequenced, the amount of data generated is significantly less than WGS, which can result in lower sequencing and analysis costs.

How much does WGS sequencing cost?

The cost of WGS typically ranges from $1,000 to $5,000 USD per human genome, depending on the sequencing depth, platform, and data analysis services.

What is one major distinction between whole genome sequencing (WGS) and targeted next generation sequencing (TNGs)?

The major distinction is that WGS sequences the entire genome, while targeted NGS sequences only selected genomic regions of interest.

Is NGS cheaper than sanger?

However, if looking to sequence in bulk, whether whole genomes or deep coverage of specific genes, NGS is cheaper and faster.

Does insurance cover exome sequencing?

Most insurance providers require pre-authorization for whole-exome or genome sequencing, meaning your healthcare provider must submit detailed clinical information demonstrating that you meet coverage criteria.

References:

1. Li C, Vandersluis S, Holubowich C, Ungar WJ, Goh ES, Boycott KM, Sikich N, Dhalla I, Ng V. Cost-effectiveness of genome-wide sequencing for unexplained developmental disabilities and multiple congenital anomalies. Genet Med. 2021 Mar;23(3):451-460.
2. Akbarzadeh Khorshidi H, Soltanolkottabi M, IJzerman MJ. Implementation of whole genome sequencing in cancer management: modelling and sensitivity analysis using system dynamics. Discov Oncol. 2025 Sep 24;16(1):1696.
3. Schwarze K, Buchanan J, Taylor JC, Wordsworth S. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 2018 Oct;20(10):1122-1130.
4. Neves LM, Pinto M, Zin OA, Cunha DP, Agonigi BNS, Motta FL, Gomes LHF, Horovitz DDG, Almeida DC Jr, Malacarne J, Guida L, Braga A, Carvalho AB, Pereira E, Rodrigues APS, Sallum JMF, Zin AA, Vasconcelos ZFM. The cost of genetic diagnosis of suspected hereditary pediatric cataracts with whole-exome sequencing from a middle-income country perspective: a mixed costing analysis. J Community Genet. 2024 Jun;15(3):235-247.
5. Vrijenhoek T, Middelburg EM, Monroe GR, van Gassen KLI, Geenen JW, Hövels AM, Knoers NV, van Amstel HKP, Frederix GWJ. Whole-exome sequencing in intellectual disability; cost before and after a diagnosis. Eur J Hum Genet. 2018 Nov;26(11):1566-1571.